[Clinical effects of intravenous ciprofloxacin on community-acquired pneumonia with positive Immunocard Mycoplasma test results].
We studied the clinical effects of intravenous ciprofloxacin (CPFX) on community-acquired pneumonia in patients with positive Immunocard Mycoplasma test results. The subjects were 35 patients (59.4 +/- 24.8 years old) with community-acquired pneumonia with positive Immunocard Mycoplasma test results. We infused CPFX 300mg copy intravenously twice daily for 3-14 days. It was effective in 33 of 35 patients, with an efficacy rate of 94.3%. Adverse reactions consisted of itching in 2 patients, malaise in 2 patients, drug eruption in 1 patient, elevation of GPT in 1 patient and elevation of BUN in 1 patient, but all were mild. We conclude that intravenous CPFX is useful for community-acquired pneumonia in case with positive Immunocard Mycoplasma test results.
Okimoto
Niro
N
Center of Respiratory Diseases, Kawasaki Medical School, Kawasaki Hospital.
Nanba
Fumiyo
F
Kibayashi
Takashi
T
Kishimoto
Michihiro
M
Yamato
Kenji
K
Kurihara
Takeyuki
T
Honda
Yoshihiro
Y
Osaki
Kohichi
K
Asaoka
Naoko
N
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000009:adverse effects; D017714:Community-Acquired Infections / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods*; D007075:Immunoglobulin M / Q000097:blood; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009174:Mycoplasma / Q000276:immunology; D009175:Mycoplasma Infections / Q000175:diagnosis* / Q000188:drug therapy*; D018410:Pneumonia, Bacterial / Q000175:diagnosis* / Q000188:drug therapy*; D011446:Prospective Studies; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D015415:Biomarkers; D007075:Immunoglobulin M; D002939:Ciprofloxacin